Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza

GlaxoSmithKline (GSK)

Status and phase: Terminated; Phase 2

Conditions: Virus Diseases

Treatments: Drug: Danirixin 50 mg FBE; Drug: Placebo; Drug: Danirixin 15 mg FBE; Drug: Oseltamivir 75 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT02927431

201023

2016-002512-40 (EudraCT Number)

Details and patient eligibility

About

Danirixin (DNX) is a novel, selective, and reversible antagonist of the C-X-C chemokine receptor (CXCR) 2 and has been shown to decrease neutrophil transmigration and activation to areas of inflammation. An intravenous (IV) formulation of DNX hydrobromide (HBr) is being developed as an anti-inflammatory agent for treatment of adults hospitalized with influenza (IFV). While early therapy with antivirals decreases severity and duration of symptoms of influenza, there are no drugs that have demonstrated clinical efficacy in randomized clinical trials in this population. Current treatment guidelines for hospitalized IFV recommend neuraminidase inhibitors as standard of care therapy. IFV studies in animals have demonstrated that therapeutic treatment with the combination of a CXCR2 antagonist and a neuraminidase inhibitor reduced lung neutrophils and showed trends for improvements in clinical scores, lung function and pathology with no evidence of worsening outcomes, including viral load. This Phase 2, randomized, double-blind (for IV DNX), placebo-controlled (for IV DNX) 3-arm study will be the first study to determine the efficacy and safety of IV DNX when co-administered (in all groups) with standard of care antiviral treatment (open-label oral oseltamivir [OSV]) in subjects hospitalized with IFV. The primary objective of the study is to assess the efficacy of treatment with IV DNX twice daily given with oral OSV compared to oral OSV twice daily on time to clinical response (TTCR). In this study, subjects will be randomized in a 2:2:1 ratio to 15 milligram (mg) free base equivalent (FBE) IV DNX, 50 mg FBE IV DNX, or matching placebo twice daily. All subjects will also receive open-label 75 mg oral OSV, twice daily (given as standard of care). The study treatment duration will be for up to 5 days. The investigator may elect to continue treatment with OSV after 5 days of study treatment. Follow up will continue until Day 45 for all subjects. The study will begin with enhanced safety monitoring in sentinel cohorts, leading to stepwise enrollment of subjects. Subjects will be enrolled based on increasing levels of renal impairment, and less severe hospitalized subjects will be enrolled prior to enrollment of critically ill subjects, as this is the first study conducted in the hospitalized population with severe IFV. Approximately 300 subjects are targeted to be enrolled in the study.

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults 18 years (as per local laws) of age and older at the time of signing the informed consent.

• Presence of fever (>=38.0 degree Celsius [>=100.4 degree Fahrenheit] by any route) at Baseline (enrollment) or history of fever/feverishness during the 48 hours prior.

• Oxygen (O2) saturation <95% on room air by trans-cutaneous method OR need for any supplemental oxygenation (non-invasive ventilation, facemask, facetent, nasal canula, etc) or ventilator support (mechanical ventilation, bi-level positive airway pressure [BIPAP], continuous positive airway pressure [CPAP]) or increase in oxygen supplementation requirement of >=2 liters for subjects with chronic oxygen dependency. For those subjects with a history of chronic hypoxia (without supplemental oxygen), an oxygen saturation of at least 3% below the subject's historical baseline oxygen saturation.

• And at least 2 out of the following 3: respiratory rate >24 breaths per minute. For those subjects who require ventilator support or oxygen supplementation, this requirement is waived; heart rate >100 beats per minute; SBP <90 millimeters of mercury (mm Hg).

• Severity of symptoms at enrollment: 1) Less severe hospitalized subjects are those who (but not limited to): are hemodynamically stable; may require oxygenation with facemask, facetent, nasal canula, etc; may or may not have radiological signs of lower respiratory tract disease; or have exacerbation of underlying chronic disease, including asthma, chronic obstructive pulmonary disease (COPD), or other cardiovascular conditions not leading to hemodynamic compromise. 2) Critically ill hospitalized subjects are those who (but not limited to): require CPAP, BIPAP, mechanical ventilation; have hemodynamic instability (with or without pressor support); or have central nervous system involvement (example encephalopathy, encephalitis).

• Presence of influenza that in the Investigator's judgment requires hospitalization for treatment and supportive care

• Onset of influenza symptoms within 6 days prior to study enrolment. Symptoms may include cough, dyspnea, sore throat, feverishness, myalgias, headache, nasal symptoms (rhinorrhea, congestion), fatigue, diarrhea, nausea and vomiting.

• A positive result from a rapid influenza test (provided by GlaxoSmithKline [GSK]) or other available, local laboratory diagnostic test

• Baseline renal criteria as follows: 1) Sentinel Cohorts: Normal renal function: Baseline creatinine clearance within normal reference ranges (>=80 milliliter per minute (mL/min) for the first approximately 30 subjects enrolled; Mild renal impairment: Baseline creatinine clearance of 50-79 mL/min for the next approximately 10 subjects enrolled into the sentinel cohort; Moderate renal impairment: Baseline creatinine clearance of 30-49 mL/min for the next approximately 10 subjects enrolled into the sentinel cohort. 2) Post-sentinel cohorts: Normal renal function, mild or moderate renal impairment: creatinine clearance >30mL/min.

• Baseline Liver Function Tests: Subjects will be included if:

  1. ALT is <=5 times the upper limit of normal (ULN) and bilirubin is <=2 times the ULN
  2. ALT is >5 but <=8 times the ULN and bilirubin is < 1.5 times the ULN

• Male or Female subjects could be eligible if: Male subjects with female partners of child bearing potential must comply with the pre-specified highly effective contraception requirements from the time of first dose of study medication until at least 36 hours (five half-lives) after the last dose of study medication. 1) Vasectomy with documentation of azoospermia 2) Male condom plus partner use of one of the contraceptive options below: Contraceptive subdermal implant; Intrauterine device or intrauterine system; Oral Contraceptive, either combined or progestogen alone; Injectable progestogen; Contraceptive vaginal ring; Percutaneous contraceptive patches

• For females, non-reproductive potential defined as: 1) Pre-menopausal females with one of the following: Documented tubal ligation; Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; Hysterectomy; Documented Bilateral Oophorectomy 2) Postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause (refer to laboratory reference ranges for confirmatory levels)]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. 3) Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from the first dose of study medication until at least 36 hours after the last dose of study medication and completion of the post treatment (PT) Day 3 visit. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.

• Subjects willing and able to give written informed consent to participate in the study and to adhere to the procedures stated in the protocol OR Legally acceptable representative (LAR) willing and able to give written informed consent on behalf of the subject to participate in the study for unconscious adults, and those incapable of consenting themselves due to their medical condition (e.g. too weak or debilitated, severe shortness of breath), due to literacy issues or included as permitted by local regulatory authorities, institutional review board (IRB)/independent ethics committee (IECs) or local laws.

• French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion criteria

• Subjects who, in the opinion of the investigator, are not likely to survive the next 48 hours beyond Baseline;

• Immunosuppression, whether due to primary immunosuppressive conditions, such as history of inherited immunodeficiency syndromes, human immunodeficiency virus (HIV) infection, or secondary conditions, such as immunosuppressive medication, stem cell or solid organ transplantation, or malignancy;

• Documented current liver disease (including Hepatitis A, B, or C), or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones);

• Baseline Liver Function Tests: Subjects will be excluded if:

  1. ALT >8 times the ULN
  2. Bilirubin is >2 times the ULN

• Corrected QT Interval (QTc) Criteria: Corrected QT Interval using Bazette's formula (QTcB) or Corrected QT Interval using Fridericia forumula (QTcF) >480 millisecond (msec) or >500 msec with bundle branch block;

• For subjects enrolled in the sentinel cohorts: diabetes mellitus and chronic kidney disease;

• Subjects who require dialysis, or are on renal replacement therapies;

• Subjects who require extra corporeal membrane oxygenation (ECMO) at baseline (enrolled subjects who subsequently require ECMO may continue in the study)

• Women who are pregnant as determined by a positive human chorionic gonadotrophin (hCG) ultrasensitive test prior to dosing or women who are breastfeeding;

• Subjects who received other treatments for influenza including vitaglutam, umifenovir, and neuraminidase inhibitors (oseltamivir, zanamivir, peramivir) for more than 72 hours during current acute illness;

• Subjects who received any immunoglobulins within 6 months of screening or planned administration of any of these products during the treatment period.

• Subjects treated with cytotoxic or immunosuppressive drugs within six months of study enrolment. Topical, intra-articularly injected, or inhaled glucocorticoids, topical calcineurin inhibitors or imiquimod are allowed.

• Known history of drug abuse within 6 months of study start.

• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.

• Absolute neutrophil count <1.0 giga per Liter (Gi/L)

• Subjects who have participated in a clinical trial using an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

10 participants in 3 patient groups, including a placebo group

Danirixin 15 mg FBE IV plus 75 mg oseltamivir

Experimental group

Description:

Subjects will receive double blind 15 mg FBE IV danirixin twice daily with open label 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.

Treatment:

Drug: Oseltamivir 75 mg

Drug: Danirixin 15 mg FBE

Danirixin 50 mg FBE IV plus 75 mg oseltamivir

Experimental group

Description:

Subjects will receive double blind 50 mg FBE IV danirixin twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.

Treatment:

Drug: Oseltamivir 75 mg

Drug: Danirixin 50 mg FBE

Placebo of danirixin IV plus 75 mg oseltamivir

Placebo Comparator group

Description:

Subjects will receive double blind IV placebo of DNX twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.

Treatment:

Drug: Oseltamivir 75 mg

Drug: Placebo